98 related articles for article (PubMed ID: 14601011)
41. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
[TBL] [Abstract][Full Text] [Related]
42. Interim analysis for randomized clinical trials: simulating the predictive distribution of the log-rank test statistic.
Chang MN; Shuster JJ
Biometrics; 1994 Sep; 50(3):827-33. PubMed ID: 7981402
[TBL] [Abstract][Full Text] [Related]
43. Monitoring clinical trials. Several points are contentious.
Parry D
BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778590
[No Abstract] [Full Text] [Related]
44. Effects of participant preferences in unblinded randomized controlled trials.
Floyd AH; Moyer A
J Empir Res Hum Res Ethics; 2010 Jun; 5(2):81-93. PubMed ID: 20569152
[TBL] [Abstract][Full Text] [Related]
45. Efficient translational rehabilitation randomised controlled trial designs using disease progress modelling and trial simulation.
Forsyth R
Neuropsychol Rehabil; 2009 Dec; 19(6):891-903. PubMed ID: 19626555
[TBL] [Abstract][Full Text] [Related]
46. Monitoring clinical trials. Caution may be warranted in releasing interim trial data.
Thornton H
BMJ; 2001 Dec; 323(7326):1424-5. PubMed ID: 11778589
[No Abstract] [Full Text] [Related]
47. Semiparametric methods for multistate survival models in randomised trials.
Hudson HM; Lô SN; Simes RJ; Tonkin AM; Heritier S
Stat Med; 2014 May; 33(10):1621-45. PubMed ID: 24338893
[TBL] [Abstract][Full Text] [Related]
48. Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments.
Korn EL; Freidlin B
J Clin Oncol; 2010 Aug; 28(24):3800-2. PubMed ID: 20660828
[No Abstract] [Full Text] [Related]
49. Experimental studies in air medical research.
Youngquist ST; Gee C
Air Med J; 2012; 31(1):7-9. PubMed ID: 22225555
[TBL] [Abstract][Full Text] [Related]
50. [Ethical problems in randomized clinical studies from the aspect of statistics. Part II: when should patient randomization be stopped of modified?].
Haas T
Cas Lek Cesk; 2003 Jan; 142(1):34-8. PubMed ID: 12693296
[TBL] [Abstract][Full Text] [Related]
51. Monitoring clinical trials. Interim data are at least as important as interim analyses.
Reidpath D
BMJ; 2001 Dec; 323(7326):1425. PubMed ID: 11778591
[No Abstract] [Full Text] [Related]
52. Mid-trial design reviews for sequential clinical trials.
Whitehead J; Whitehead A; Todd S; Bolland K; Sooriyarachchi MR
Stat Med; 2001 Jan; 20(2):165-76. PubMed ID: 11169595
[TBL] [Abstract][Full Text] [Related]
53. Blinded versus unblinded covariate selection in confirmatory survival trials.
Kunz C; Kieser M
J Biopharm Stat; 2014; 24(2):398-414. PubMed ID: 24605976
[TBL] [Abstract][Full Text] [Related]
54. Eligibility, extrapolation and equipoise: unlearned lessons in the ethical analysis of clinical research.
Crouch RA
IRB; 2001; 23(4):6-9. PubMed ID: 11837285
[No Abstract] [Full Text] [Related]
55. Monitoring clinical trials. Interim data should not be publicly available.
Richards SM
BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11778588
[No Abstract] [Full Text] [Related]
56. Bayesian clinical trial design using Markov models with applications to autoimmune disease.
Eggleston BS; Ibrahim JG; Catellier D
Contemp Clin Trials; 2017 Dec; 63():73-83. PubMed ID: 28188841
[TBL] [Abstract][Full Text] [Related]
57. ESPRIT trial.
Filippi A
Lancet; 2006 Aug; 368(9534):447-8; author reply 449. PubMed ID: 16890823
[No Abstract] [Full Text] [Related]
58. Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.
Bird SM
BMJ; 2001 Dec; 323(7326):1424. PubMed ID: 11744570
[No Abstract] [Full Text] [Related]
59. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections.
Schäfer H; Müller HH
Stat Med; 2001 Dec; 20(24):3741-51. PubMed ID: 11782030
[TBL] [Abstract][Full Text] [Related]
60. How to estimate the effect of treatment duration on survival outcomes using observational data.
Hernán MA
BMJ; 2018 Feb; 360():k182. PubMed ID: 29419381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
